Mr. Grenfell-Gardner has served as the President and Chief Executive Officer and a member of the Board of Directors of Teligent, Inc., a specialty generic pharmaceutical company, since 2012. From 2008 to 2012, Mr. Grenfell-Gardner served in various management roles, and most recently as Senior Vice President of Sales and Marketing of Hikma Pharmaceuticals, PLC and its subsidiaries, including West-Ward Pharmaceuticals, a pharmaceutical company. From 1998 to 2003, Mr. Grenfell-Gardner worked throughout Central and Eastern Europe as a partner at Trigon Capital, a boutique investment bank focused on mergers and acquisitions. During his time in that region, Mr. Grenfell-Gardner served as chairman of the board of directors of AB Sanitas, as well as other board positions. Mr. Grenfell-Gardner holds an M.A. (Hons) in Economics from the University of St. Andrews in Scotland and an MBA from INSEAD.
Robin D. Campbell
Dr. Campbell joined our board of directors in September 2014. He has over 25 years of experience in pharmaceutical and biotechnology sales, marketing, product development and general management in both the U.S. and in international markets. Currently he serves as Chairman of the Board of Aptitude Medical Systems, an early stage company creating high performance aptamers for research, diagnostic and therapeutic use. He is also a Lecturer in the Technology Management Program of the College of Engineering at the University of California at Santa Barbara. From 2004 to 2008, Dr. Campbell was President and CEO of Naryx Pharma, a venture-backed specialty pharmaceutical company developing novel, topically delivered treatments for chronic sinusitis and other conditions treatable by intranasal drug delivery. Prior to joining Naryx Pharma, Dr. Campbell was at Amgen from 1989 to 2002, where his most recent position was Vice President and General Manager, U.S. Oncology Business Unit. In this position, he led an integrated team responsible for the marketing, sales and medical development of products generating over $1 billion of annual sales including Neupogen and Neulasta. His professional experience also includes sales, marketing and managerial responsibilities with Ciba-Geigy Corporation from 1984 to 1989. He earned a Bachelor of Arts in Zoology at the University of North Carolina at Chapel Hill, and a Ph.D. in Microbiology and Immunology at the Bowman Gray School of Medicine of Wake Forest University.
Phillip M. Schneider
Phillip M. Schneider joined our board in connection with Pfenex’s initial public offering in July 2014. Most recently, Mr. Schneider held various positions with IDEC Pharmaceuticals Corporation, a biopharmaceutical company, from 1987 to 2003, including: Senior Vice President and Chief Financial Officer from 1997 to 2003; and Director of Finance and Administration from 1992 to 1997. Prior to that, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation, a pharmaceutical company, from 1985 to 1987 and KPMG LLP, an audit and tax advisory firm, from 1982 to 1984, where he attained his CPA license. He currently serves as a member of the board of directors of Arena Pharmaceuticals Corporation, a pharmaceutical company, which he joined in 2008, and Auspex Pharmaceuticals, a pharmaceutical company, which he joined in 2014. He previously served as a member of the board of directors of Gen-Probe, Inc., a biotechnology company, from 2002 to 2012. Mr. Schneider holds a B.S. in Biochemistry from the University of California, Davis and an M.B.A. from the University of Southern California.
John Taylor joined our board of directors in April 2015. He is a Principal at Greenleaf Health LLC., and has over 24 years of experience working on Food and Drug related issues at the at the U.S. Food and Drug Administration (FDA) and in private industry. He is a member of Greenleaf’s Compliance & Regulatory Affairs group. Prior to joining Greenleaf in 2014, he served in three positions at FDA: Counselor to the Commissioner; Acting Deputy Principal Commissioner; and Acting Deputy Commissioner for Global Regulatory Operations and Policy.
John began his career at FDA as an attorney within FDA’s Office of the Chief Counsel in 1991. In 1997, John was promoted to Senior Advisor for Regulatory Operations and Policy within FDA’s Office of the Commissioner; he was later named Director of the Center for Drug Evaluation and Research’s Office of Compliance. In 2000, John became the Director of the Office of Enforcement in FDA’s Office of Regulatory Affairs (ORA). Two years later, John was promoted to Associate Commissioner for Regulatory Affairs. In that role he was responsible for managing ORA.
In 2005, John left FDA and spent four years working in the private sector, first as Divisional Vice President for Federal Government Affairs at Abbott, then, in 2007, as Executive Vice President for Health at the Biotechnology Industry Organization. He also served on the Board of Directors for the Food and Drug Law Institute from 2007 to 2009. In 2009, John returned to FDA.
John received a Bachelor of Arts in History from Pennsylvania State University and a Juris Doctorate degree from the College of William and Mary.
Dennis Fenton joined the board of directors in September 2015, deepening the manufacturing and product development expertise of our company. Dr. Fenton, an industry pioneer, has over three decades of experience in the biotechnology industry.
Dr. Fenton retired after a lengthy and distinguished career with Amgen, where he held a variety of notable roles, including Executive Vice President, Operations. Prior to Amgen, he was a senior researcher with Pfizer. Dr. Fenton most recently served on the board of directors of Hospira, Dendreon Corporation, Genzyme and Amira Pharmaceuticals.
He is an alumnus of Rutgers University, where he graduated with a Ph.D. in microbiology. Dr. Fenton currently serves as a member of the board of directors for Portola Pharmaceuticals, XenoPort, Nora Therapeutics, and Kythera Biopharmaceuticals.
Sigurdur (Siggi) Olafsson
Mr. Olafsson served as President and Chief Executive Officer, Global Generic Medicines Group of Teva Pharmaceuticals Ltd., a pharmaceutical company, from 2014 until his retirement in March 2017. Mr. Olafsson previously served as President of Actavis Pharma, Inc., a pharmaceutical company, from 2012 to 2014, Executive Vice President, Global Generics, at Actavis plc (Watson) from 2010 to 2012 and CEO of the Actavis Group from 2008 to 2010. From 2003 to 2008, he held positions of increasing responsibility within the Actavis Group, including Deputy CEO, Vice President of Corporate Development and CEO of Actavis Inc. U.S. From 1998 to 2003, he held positions of increasing responsibility with the Global R&D organization in the U.K. and U.S. of Pfizer Inc., a pharmaceutical company. From 1994 to 1998, he served as Head of Drug Development for Omega Farma, a pharmaceutical company, in Iceland. Mr. Olafsson received a M.S. in pharmacy (Cand Pharm) from the University of Iceland, Reykjavik.